RASSF4 Inhibitors
Chemical inhibitors of RASSF4 can exert their effects through various mechanisms by targeting specific pathways that RASSF4 is known to interact with. For example, NSC 74859, also known as S3I-201, targets the STAT3 transcription factor, which is a downstream component of signaling cascades that RASSF4 is involved with. By inhibiting STAT3, the transcription of genes critical for RASSF4-mediated signaling can be reduced, leading to its functional inhibition. Similarly, GW5074, an inhibitor of Raf-1 kinase, and Sorafenib, a multikinase inhibitor that targets Raf kinases, both act to suppress the MAPK/ERK pathway activity. Since RASSF4 interacts with the Ras family and is associated with the MAPK/ERK pathway, these chemicals can impede the phosphorylation and activation of downstream effectors that are essential for RASSF4 function. ZM 336372 furthers this effect by inhibiting Raf kinase activation, which is crucial for MAPK/ERK pathway signaling and RASSF4 functionality.
Additional chemical inhibitors like SP600125 and SB203580 target other MAPK pathways, such as JNK and p38 MAPK. Inhibition of these kinases by SP600125 and SB203580 can decrease the activity of transcription factors and other signaling molecules that RASSF4 may regulate, resulting in its functional inhibition. LY294002 and Wortmannin are potent PI3K inhibitors, and since PI3K signaling is integral to the Ras signaling network, their application can disrupt the downstream signaling required for RASSF4's role in cell survival and proliferation. PD98059 and U0126, both MEK inhibitors, prevent the activation of ERK1/2 in the MAPK pathway, thereby impeding the functional activity of RASSF4. Rapamycin, as an mTOR inhibitor, takes a different approach by inhibiting mTOR signaling, which is associated with the Ras pathway and crucial for RASSF4's role in growth factor signaling. Lastly, Bisindolylmaleimide I inhibits protein kinase C (PKC), affecting numerous signaling pathways, including those involving RASSF4, leading to downstream effects that functionally inhibit RASSF4's activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is an inhibitor of Raf-1 kinase, which is part of the MAPK/ERK pathway. RASSF4 is associated with this pathway through its interaction with the Ras family. By inhibiting Raf-1, GW5074 can prevent the activation of downstream effectors that are essential for RASSF4 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. The JNK pathway is another MAPK pathway that, when inhibited, can decrease the activity of transcription factors and other signaling molecules that RASSF4 may regulate or interact with, thus effectively inhibiting RASSF4's function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound is a known inhibitor of p38 MAPK. As RASSF4 is involved with MAPK signaling pathways, inhibition of p38 MAPK by SB203580 can interfere with the signaling cascade involving RASSF4, resulting in its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. PI3K signaling is connected to the Ras signaling network, with which RASSF4 is involved. Inhibition of PI3K can disrupt downstream signaling required for RASSF4's participation in cell survival and proliferation processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of ERK in the MAPK pathway. Since RASSF4 is connected with the MAPK pathway, inhibiting MEK with PD98059 can lead to reduced ERK activation and thereby inhibit RASSF4's functional role. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor, which prevents the activation of ERK1/2. As ERK is downstream of RASSF4 in the MAPK pathway, the inhibition of MEK by U0126 can impede the functional activity of RASSF4. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $47.00 | 2 | |
ZM 336372 is primarily a Raf kinase inhibitor, which could inhibit the activation of the MAPK/ERK pathway. RASSF4's function is related to this pathway, and thus its inhibition would lead to a functional inhibition of RASSF4. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multikinase inhibitor that targets Raf kinases. By inhibiting Raf, Sorafenib can suppress the MAPK/ERK pathway activity, subsequently inhibiting RASSF4's role in this signaling cascade. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. Given that PI3K is a part of the signaling pathways that RASSF4 is involved in, inhibition of PI3K by Wortmannin can lead to the functional inhibition of RASSF4. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, and since mTOR signaling is associated with the Ras pathway, inhibiting mTOR can lead to the functional inhibition of RASSF4 due to its role in growth factor signaling. | ||||||